Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Pain and Therapy

Open Access 21-09-2024 | Opioids | REVIEW

Present and Future of Pharmacological Management for Acute Moderate-to-Severe Postoperative, Traumatic, or Musculoskeletal Pain in Europe: A Narrative Review

Authors: Eugene R. Viscusi, Francisco Epelde, Luis Javier Roca Ruiz, Eva Trillo-Calvo

Published in: Pain and Therapy

Login to get access

Abstract

Acute moderate-to-severe pain is common after surgery, trauma, or musculoskeletal injury, but its management remains suboptimal. Current single-agent treatments are limited by safety concerns, narrow therapeutic windows, and abuse potential, leaving substantial unmet needs. Here, we aimed to review guidelines for the management of acute moderate-to-severe post-surgical, trauma-related, or musculoskeletal pain in adults and discuss existing and potential future analgesics in this setting. We searched PubMed to identify relevant guidelines and existing analgesics for acute pain. To identify compounds in development, we searched ClinicalTrials.gov and the European Union Clinical Trials Register. Guidelines universally recognize the limitations of single-agent analgesics (particularly those with a single mechanism of action [MoA]) and recommend a multimodal approach as an established standard for acute pain. The benefit–risk profiles of traditional treatments, including paracetamol (acetaminophen), nonsteroidal anti-inflammatory drugs, selective cyclooxygenase-2 inhibitors, and opioids, can be improved by combining agents targeting different pain pathways. In multimodal approaches, lower doses of constituent agents can be used to achieve the same or superior analgesic effects relative to the individual agents. In some cases, novel formulations and co-crystal technology offer enhanced physicochemical and pharmacokinetic properties over individual agents. Lastly, initiatives to increase patient awareness and education around pain management may improve treatment satisfaction and quality of life, and hasten recovery. In conclusion, management of acute moderate-to-severe pain remains inadequate. Multimodal analgesics may offer advantages over traditional single-agent treatments (that often have a single MoA) for acute moderate-to-severe post-surgical, trauma-related, or musculoskeletal pain in adults. Multimodal analgesics, combined with patient education initiatives and non-pharmacological measures, when necessary, offer promise in addressing unmet needs in this setting.
Literature
1.
Qaseem A, McLean RM, O’Gurek D, et al. Nonpharmacologic and pharmacologic management of acute pain from non-low back, musculoskeletal injuries in adults: a clinical guideline from the American College of Physicians and American Academy of Family Physicians. Ann Intern Med. 2020;173(9):739–48.PubMedCrossRef
2.
3.
Gregory J, McGowan L. An examination of the prevalence of acute pain for hospitalised adult patients: a systematic review. J Clin Nurs. 2016;25(5–6):583–98.PubMedCrossRef
4.
Cinar O, Blankenship J, Fosnocht D, et al. Pain management practices in the emergency department: 10 years of experience in an academic center. Ann Emerg Med. 2011;58(4S):S227.CrossRef
5.
Gan TJ, Epstein RS, Leone-Perkins ML, Salimi T, Iqbal SU, Whang PG. Practice patterns and treatment challenges in acute postoperative pain management: a survey of practicing physicians. Pain Ther. 2018;7(2):205–16.PubMedPubMedCentralCrossRef
6.
Gerbershagen HJ, Aduckathil S, van Wijck AJ, Peelen LM, Kalkman CJ, Meissner W. Pain intensity on the first day after surgery: a prospective cohort study comparing 179 surgical procedures. Anesthesiology. 2013;118(4):934–44.PubMedCrossRef
7.
8.
Joshi GP. Enhanced recovery pathways for ambulatory surgery. Curr Opin Anaesthesiol. 2020;33(6):711–7.PubMedCrossRef
9.
10.
Fletcher D, Stamer UM, Pogatzki-Zahn E, et al. Chronic postsurgical pain in Europe: an observational study. Eur J Anaesthesiol. 2015;32(10):725–34.PubMedCrossRef
11.
Glare P, Aubrey KR, Myles PS. Transition from acute to chronic pain after surgery. Lancet. 2019;393(10180):1537–46.PubMedCrossRef
12.
Rosenberger DC, Pogatzki-Zahn EM. Chronic post-surgical pain - update on incidence, risk factors and preventive treatment options. BJA Educ. 2022;22(5):190–6.PubMedPubMedCentralCrossRef
13.
Gan TJ, Habib AS, Miller TE, White W, Apfelbaum JL. Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey. Curr Med Res Opin. 2014;30(1):149–60.PubMedCrossRef
14.
Abdolrazaghnejad A, Banaie M, Tavakoli N, Safdari M, Rajabpour-Sanati A. Pain management in the emergency department: a review article on options and methods. Adv J Emerg Med. 2018;2(4): e45.PubMedPubMedCentral
15.
Arfè A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016;354: i4857.PubMedCrossRef
16.
Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12):1127–46.PubMedPubMedCentralCrossRef
17.
Oderda GM, Senagore AJ, Morland K, et al. Opioid-related respiratory and gastrointestinal adverse events in patients with acute postoperative pain: prevalence, predictors, and burden. J Pain Palliat Care Pharmacother. 2019;33(3–4):82–97.PubMedCrossRef
18.
Varrassi G, Hanna M, Macheras G, et al. Multimodal analgesia in moderate-to-severe pain: a role for a new fixed combination of dexketoprofen and tramadol. Curr Med Res Opin. 2017;33(6):1165–73.PubMedCrossRef
19.
Raffa RB, Pergolizzi JV Jr, Tallarida RJ. The determination and application of fixed-dose analgesic combinations for treating multimodal pain. J Pain. 2010;11(8):701–9.PubMedPubMedCentralCrossRef
20.
Feizerfan A, Sheh G. Transition from acute to chronic pain. BJA Educ. 2015;15(2):98–102.
21.
Joshi GP, Van de Velde M, Kehlet H, PROSPECT Working Group Collaborators. Development of evidence-based recommendations for procedure-specific pain management: PROSPECT methodology. Anaesthesia. 2019;74(10):1298–304.
22.
23.
Abebe MM, Arefayne NR, Temesgen MM, Admass BA. Evidence-based perioperative pain management protocol for day case surgery in a resource limited setting: systematic review. Ann Med Surg (Lond). 2022;80: 104322.PubMed
24.
Anekar AA, Hendrix JM, Cascella M. WHO Analgesic Ladder. Treasure Island (FL): StatPearls Publishing; 2024.
25.
Maessen T, Korir N, Van de Velde M, et al. Pain management after cardiac surgery via median sternotomy: a systematic review with procedure-specific postoperative pain management (PROSPECT) recommendations. Eur J Anaesthesiol. 2023;40(10):758–68.PubMedCrossRef
26.
27.
Roca Ruiz LJ, Ruiz Iban MA, Heredia JD, Lopez-Millan JM. Consensus on the preoperative management of patients with chronic moderate to severe shoulder pain to improve postoperative outcomes: Delphi results. J Shoulder Elbow Surg. 2024;S1058–2746(23):00895–9.
28.
29.
30.
31.
Vargas-Schaffer G. Is the WHO analgesic ladder still valid? Twenty-four years of experience. Can Fam Physician. 2010;56(6):514–7, e202–5.
32.
Gianola S, Bargeri S, Del Castillo G, et al. Effectiveness of treatments for acute and subacute mechanical non-specific low back pain: a systematic review with network meta-analysis. Br J Sports Med. 2022;56(1):41–50.PubMedCrossRef
33.
34.
Moore RA, Derry S, Aldington D, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews. Cochrane Database Syst Rev. 2015;2015(9):CD008659.
35.
36.
Pelletier JP, Martel-Pelletier J, Rannou F, Cooper C. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016;45(Suppl. 4):S22–7.PubMedCrossRef
37.
Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821–47.PubMedCrossRef
38.
Bouck Z, Mecredy GC, Ivers NM, et al. Frequency and associations of prescription nonsteroidal anti-inflammatory drug use among patients with a musculoskeletal disorder and hypertension, heart failure, or chronic kidney disease. JAMA Intern Med. 2018;178(11):1516–25.PubMedPubMedCentralCrossRef
39.
McDonald J, McBain L, Dowell AC, Morris C. GPs’ views and experiences of prescribing non-steroidal anti-inflammatory drugs: a qualitative study. BJGP Open. 2017;1(2):bjgpopen17X100869.
40.
Crichton B, Green M. GP and patient perspectives on treatment with non-steroidal anti-inflammatory drugs for the treatment of pain in osteoarthritis. Curr Med Res Opin. 2002;18(2):92–6.PubMedCrossRef
41.
Jiang M, Deng H, Chen X, Lin Y, Xie X, Bo Z. The efficacy and safety of selective COX-2 inhibitors for postoperative pain management in patients after total knee/hip arthroplasty: a meta-analysis. J Orthop Surg Res. 2020;15(1):39.PubMedPubMedCentralCrossRef
42.
Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002;325(7365):619.PubMedPubMedCentralCrossRef
43.
Essex MN, Zhang RY, Berger MF, Upadhyay S, Park PW. Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials. Expert Opin Drug Saf. 2013;12(4):465–77.PubMedCrossRef
44.
Moore A, Makinson G, Li C. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials. Arthritis Res Ther. 2013;15(1):R6.PubMedPubMedCentralCrossRef
45.
Rostom A, Muir K, Dube C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007;5(7):818–28, 28.e1–5.
46.
47.
Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519–29.PubMedCrossRef
48.
49.
Topol EJ. Failing the public health–rofecoxib, Merck, and the FDA. N Engl J Med. 2004;351(17):1707–9.PubMedCrossRef
50.
Schmidt M, Lamberts M, Olsen AM, et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother. 2016;2(2):108–18.PubMedCrossRef
51.
52.
Fabbri A, Voza A, Riccardi A, Serra S, Iaco F, Study and Research Center of the Italian Society of Emergency Medicine (SIMEU). The pain management of trauma patients in the emergency department. J Clin Med. 2023;12(9):3289.PubMedPubMedCentralCrossRef
53.
Pirie K, Traer E, Finniss D, Myles PS, Riedel B. Current approaches to acute postoperative pain management after major abdominal surgery: a narrative review and future directions. Br J Anaesth. 2022;129(3):378–93.PubMedCrossRef
54.
Krantz MJ, Palmer RB, Haigney MCP. Cardiovascular complications of opioid use: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77(2):205–23.PubMedCrossRef
55.
Langford RM, Knaggs R, Farquhar-Smith P, Dickenson AH. Is tapentadol different from classical opioids? A review of the evidence. Br J Pain. 2016;10(4):217–21.PubMedPubMedCentralCrossRef
56.
Persich P, Engels GE, van Oeveren W, Galia E, Benay S, Thun S. Development of an in vitro system and model-based translational framework to assess haemolysis risk following intravenous abuse of medications containing polyethylene oxide. Toxicol In Vitro. 2020;65:104776.PubMedCrossRef
57.
Pollack CV Jr, Viscusi ER. Improving acute pain management in emergency medicine. Hosp Pract (1995). 2015;43(1):36–45.PubMedCrossRef
58.
Sinatra R. Causes and consequences of inadequate management of acute pain. Pain Med. 2010;11(12):1859–71.PubMedCrossRef
59.
Butti L, Bierti O, Lanfrit R, et al. Evaluation of the effectiveness and efficiency of the triage emergency department nursing protocol for the management of pain. J Pain Res. 2017;10:2479–88.PubMedPubMedCentralCrossRef
60.
61.
62.
Häuser W, Buchser E, Finn DP, et al. Is Europe also facing an opioid crisis? A survey of European Pain Federation chapters. Eur J Pain. 2021;25(8):1760–9.PubMedCrossRef
63.
Kalkman GA, Kramers C, van den Brink W, Schellekens AFA. The North American opioid crisis: a European perspective. Lancet. 2022;400(10361):1404.PubMedCrossRef
64.
Godman B, McCabe H, Leong TD. Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Rev Pharmacoecon Outcomes Res. 2020;20(1):1–26.PubMedCrossRef
65.
Daniels SE, Atkinson HC, Stanescu I, Frampton C. Analgesic efficacy of an acetaminophen/ibuprofen fixed-dose combination in moderate to severe postoperative dental pain: a randomized, double-blind, parallel-group, placebo-controlled trial. Clin Ther. 2018;40(10):1765-76.e5.PubMedCrossRef
66.
Moore RA, Gay-Escoda C, Figueiredo R, et al. Dexketoprofen/tramadol: randomised double-blind trial and confirmation of empirical theory of combination analgesics in acute pain. J Headache Pain. 2015;16:541.PubMedCrossRef
67.
Schug SA. Combination analgesia in 2005 - a rational approach: focus on paracetamol-tramadol. Clin Rheumatol. 2006;25(Suppl. 1):S16-21.PubMedCrossRef
68.
Gay-Escoda C, Hanna M, Montero A, et al. Tramadol/dexketoprofen (TRAM/DKP) compared with tramadol/paracetamol in moderate to severe acute pain: results of a randomised, double-blind, placebo and active-controlled, parallel group trial in the impacted third molar extraction pain model (DAVID study). BMJ Open. 2019;9(2): e023715.PubMedPubMedCentralCrossRef
69.
O’Brien J, Pergolizzi JV Jr, van de Laar M, et al. Fixed-dose combinations at the front line of multimodal pain management: perspective of the nurse-prescriber. Nurs Res Rev. 2013;2013(3):9–22.CrossRef
70.
Pergolizzi J, Varrassi G, LeQuang JAK, Breve F, Magnusson P. Fixed dose versus loose dose: analgesic combinations. Cureus. 2023;15(1): e33320.PubMedPubMedCentral
71.
72.
Gascon N, Almansa C, Merlos M, et al. Co-crystal of tramadol-celecoxib: preclinical and clinical evaluation of a novel analgesic. Expert Opin Investig Drugs. 2019;28(5):399–409.PubMedCrossRef
73.
Langford R, Margarit C, Morte A, et al. Co-crystal of tramadol–celecoxib (CTC) for acute moderate-to-severe pain. Curr Med Res Opin. 2024;40(3):455–68.PubMedCrossRef
74.
75.
Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain — United States, 2022. MMWR Recomm Rep. 2022;71(3):1–95.PubMedPubMedCentralCrossRef
76.
Langford R, Morte A, Sust M, et al. Efficacy and safety of co-crystal of tramadol-celecoxib (CTC) in acute moderate-to-severe pain after abdominal hysterectomy: a randomized, double-blind, phase 3 trial (STARDOM2). Eur J Pain. 2022;26(10):2083–96.PubMedPubMedCentralCrossRef
77.
Viscusi ER, de Leon-Casasola O, Cebrecos J, et al. Celecoxib-tramadol co-crystal in patients with moderate-to-severe pain following bunionectomy with osteotomy: a phase 3, randomized, double-blind, factorial, active- and placebo-controlled trial. Pain Pract. 2023;23(1):8–22.PubMedCrossRef
78.
Langford R, Pogatzki-Zahn EM, Morte A, et al. Co-crystal of tramadol-celecoxib versus tramadol or placebo for acute moderate to severe pain after oral surgery: randomized, double blind, phase 3 trial (STARDOM1). Adv Ther. 2024;41(3):1025–45.PubMedPubMedCentralCrossRef
79.
80.
Gan TJ, Schachtel BP, Zhang B. Comparative effectiveness of CL-108 and ibuprofen for acute postoperative pain. J Pain. 2019;20(4):S54.
81.
Zuniga JR, Papas AS, Daniels SE, et al. Prevention of opioid-induced nausea and vomiting during treatment of moderate to severe acute pain: a randomized placebo-controlled trial comparing CL-108 (hydrocodone 7.5 mg/acetaminophen 325 mg/rapid-release, low-dose promethazine 12.5 mg) with conventional hydrocodone 7.5 mg/acetaminophen 325 mg. Pain Med. 2019;20(12):2528–38.PubMedCrossRef
82.
83.
Herman TF, Santos C. First-pass effect. Treasure Island (FL): StatPearls Publishing; 2023.
84.
Chiou WL. Estimation of hepatic first-pass effect of acetaminophen in humans after oral administration. J Pharm Sci. 1975;64(10):1734–5.PubMedCrossRef
85.
86.
Gelotte CK, Vakil AM, Berwaerts J, et al. First-in-human study to evaluate the safety, tolerability and pharmacokinetics of a novel analgesic and antipyretic drug with structural similarity to acetaminophen. Regul Toxicol Pharmacol. 2022;134: 105236.PubMedCrossRef
87.
Zhou J, De Jonghe S, Codd EE, et al. Preclinical safety assessment of JNJ-10450232 (NTM-006), a structural analog of acetaminophen, that does not cause hepatotoxicity at supratherapeutic doses. Regul Toxicol Pharmacol. 2023:105334 (online ahead of print).
88.
Gelotte CK, Vakil AM, Zimmerman BA, et al. JNJ-10450232 (NTM-006), a novel non-opioid with structural similarities to acetaminophen, produces relatively long-lasting analgesia after a single dose in patients undergoing 3rd molar extraction. Regul Toxicol Pharmacol. 2023:105480 (online ahead of print).
89.
Khanna IK, Pillarisetti S. Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res. 2015;8:859–70.PubMedPubMedCentral
90.
91.
92.
Mariano ER, Dickerson DM, Szokol JW, et al. A multisociety organizational consensus process to define guiding principles for acute perioperative pain management. Reg Anesth Pain Med. 2022;47(2):118–27.PubMedCrossRef
93.
Swenson C, Prashar N, Mangino A, Thode HC, Singer AJ. Preference for opioids in emergency department patients with acute musculoskeletal pain. Am J Emerg Med. 2019;37(4):730–2.PubMedCrossRef
94.
Walton LL, Duff E, Arora RC, McMillan DE. Surgery patients’ perspectives of their role in postoperative pain: a scoping review. Int J Nurs Stud Adv. 2023;5: 100124.PubMedPubMedCentralCrossRef
95.
Walton DM, Marsh J. The Multidimensional Symptom Index: a new patient-reported outcome for pain phenotyping, prognosis and treatment decisions. Eur J Pain. 2018;22(7):1351–61.PubMedCrossRef
96.
Komann M, Baumbach P, Stamer UM, et al. Desire to receive more pain treatment - a relevant patient-reported outcome measure to assess quality of post-operative pain management? Results from 79,996 patients enrolled in the pain registry QUIPS from 2016 to 2019. J Pain. 2021;22(6):730–8.PubMedCrossRef
97.
Pogatzki-Zahn EM, Liedgens H, Hummelshoj L, et al. Developing consensus on core outcome domains for assessing effectiveness in perioperative pain management: results of the PROMPT/IMI-PainCare Delphi Meeting. Pain. 2021;162(11):2717–36.PubMedCrossRef
98.
Forget P, Patullo C, Hill D, et al. System-level policies on appropriate opioid use, a multi-stakeholder consensus. BMC Health Serv Res. 2022;22(1):329.PubMedPubMedCentralCrossRef
99.
Aldamluji N, Burgess A, Pogatzki-Zahn E, Raeder J, Beloeil H, Prospect Working Group collaborators*. PROSPECT guideline for tonsillectomy: systematic review and procedure-specific postoperative pain management recommendations. Anaesthesia. 2021;76(7):947–61.
100.
Ghlichloo I, Gerriets V. Nonsteroidal anti-inflammatory drugs (NSAIDs). Treasure Island (FL): StatPearls Publishing; 2023.
101.
Patrono C, Baigent C. Nonsteroidal anti-inflammatory drugs and the heart. Circulation. 2014;129(8):907–16.PubMedCrossRef
102.
103.
Edinoff AN, Kaplan LA, Khan S, et al. Full opioid agonists and tramadol: pharmacological and clinical considerations. Anesth Pain Med. 2021;11(4): e119156.PubMedPubMedCentralCrossRef
104.
105.
Chou R, Griffin JC, Blazina I, Schwarz E, Atchison C, Mauer K. Systematic review on treatments for acute pain: surveillance report 1. Literature update period: August 2020 through October 2021. In: Treatments for Acute Pain: A Systematic Review: Surveillance Reports. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020.
106.
Farsi D, Movahedi M, Hafezimoghadam P, Abbasi S, Shahlaee A, Rahimi-Movaghar V. Acute pain management with intravenous 0.10 mg/kg vs. 0.15 mg/kg morphine sulfate in limb traumatized patients: a randomized double-blinded placebo-controlled trial. Ulus Travma Acil Cerrahi Derg. 2013;19(5):398–404.PubMedCrossRef
107.
108.
109.
Almansa C, Mercè R, Tesson N, Farran J, Tomàs J, Plata-Salamán CR. Co-crystal of tramadol hydrochloride−celecoxib (CTC): a novel API−API co-crystal for the treatment of pain. Cryst Growth Des. 2017;17(4):1884–92.CrossRef
110.
Cebrecos J, Carlson JD, Encina G, et al. Celecoxib-tramadol co-crystal: a randomized 4-way crossover comparative bioavailability study. Clin Ther. 2021;43(6):1051–65.PubMedCrossRef
111.
Videla S, Lahjou M, Vaque A, et al. Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. Br J Clin Pharmacol. 2018;84(1):64–78.PubMedCrossRef
112.
Port A, Almansa C, Enrech R, Bordas M, Plata-Salaman C. Differential solution behavior of the new API−API co-crystal of tramadol−celecoxib (CTC) versus its constituents and their combination. Cryst Growth Des. 2019;19(6):3172–82.CrossRef
113.
Dunn KE, Bergeria CL, Huhn AS, Strain EC. A systematic review of laboratory evidence for the abuse potential of tramadol in humans. Front Psychiatry. 2019;10:704.PubMedPubMedCentralCrossRef
114.
Jozwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Pol Pharm. 2014;71(1):11–23.PubMed
115.
Girard P, Chauvin M, Verleye M. Nefopam analgesia and its role in multimodal analgesia: a review of preclinical and clinical studies. Clin Exp Pharmacol Physiol. 2016;43(1):3–12.PubMedCrossRef
116.
Chen XH, Bai JY, Shen F, Bai AP, Guo ZR, Cheng GF. Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Acta Pharmacol Sin. 2004;25(7):927–31.PubMed
Metadata
Title
Present and Future of Pharmacological Management for Acute Moderate-to-Severe Postoperative, Traumatic, or Musculoskeletal Pain in Europe: A Narrative Review
Authors
Eugene R. Viscusi
Francisco Epelde
Luis Javier Roca Ruiz
Eva Trillo-Calvo
Publication date
21-09-2024
Publisher
Springer Healthcare
Published in
Pain and Therapy
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI
https://doi.org/10.1007/s40122-024-00645-y

2024 ESC Congress

Noise pollution dangerous for heart health

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Read more

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits